Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Raza Ur Rehman, Bachelor of Medicine and Surgery at Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, shared on LinkedIn:
”Publication Alert
Thrilled to share that our Open Access commentary has been published in Health science Reports (Wiley )
Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Health Science Reports | Volume 9, Issue 1
(e71702)
Raza Ur Rehman, Rida Fatima, Aymar AKILIMALI
Published: 29 December 2025
This article explores Fitusiran, a groundbreaking RNAi-based antithrombin-targeting therapy, marking a paradigm shift toward factor-independent prophylaxis in hemophilia management.
• Read here.
Honored to contribute to the evolving landscape of hemophilia therapeutics and RNA-based medicine.
Feedback and discussions are most welcome!”
Article: Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Authors: Raza Ur Rehman, Rida Fatima, Aymar Akilimali
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 17, 2026, 16:34ISTH Names Five Global Recipients of 2026 Esteemed Career Awards
-
Feb 17, 2026, 16:16Flora Peyvandi: A Multicenter Initiative to Improve Guideline Adherence in Pediatric ITP
-
Feb 17, 2026, 16:14Hendrianus The: Intravenous Cangrelor in Hemodynamically Unstable Patients Undergoing PCI
-
Feb 17, 2026, 15:42Paul Wischmeyer: Nutrient Absorption in the GI Tract
-
Feb 17, 2026, 15:40Mahesan Subramaniam: Reversing Age-Related Decline in Blood Stem Cells
-
Feb 17, 2026, 15:38Wolfgang Miesbach: How a Single Mutation Can Flip Immunity into VITT
-
Feb 17, 2026, 15:34Jeff June: When Safety Warnings Outlive the Evidence – What Statins Teach Us About Stroke Prevention and Biology
-
Feb 17, 2026, 15:32Gabrielle Sarlon: Key Messages to Improve VTE Management in Women of Childbearing Age
-
Feb 17, 2026, 15:27Piezo1 Gain-of-Function Mutation Explains Thromboembolic Complications in Hereditary Xerocytosis – JTH